Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Burkitt Lymphoma 3Blast Crisis 3Anemia, Refractory, with Excess of Blasts 3Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Accelerated Phase 2Leukemia 2Hodgkin Disease 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Sezary Syndrome 1Recurrence 1Precancerous Conditions 1Polycythemia Vera 1Plasmablastic Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms, Plasma Cell 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Dexamethasone 2Calcium Dobesilate 2iberdomide 1daratumumab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Peripheral Blood Stem Cell Transplantation × 30 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡